Skip to main
BSX
BSX logo

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 47%
Buy 53%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific has demonstrated substantial sales growth across multiple product lines, with Watchman sales increasing by 35% year-over-year, driven by strong adoption in related procedures, and electrophysiology (EP) sales surging by 63%, indicating robust market demand and share gains. The company's guidance for Q4 suggests a positive outlook with expected organic sales growth of 11-13% and projected GAAP EPS between $0.48 and $0.52, reflecting solid operational performance and anticipated revenue generation. Additionally, Boston Scientific's innovations, such as the Nalu device projected to exceed $60 million in sales by 2025 and contribute to a growth rate over 25% in 2026, showcase the firm's effective product pipeline and potential for future profitability in the expanding medical device sector.

Bears say

Boston Scientific is facing a challenging financial landscape, primarily due to expected foreign exchange headwinds, which are projected to negatively impact adjusted earnings by approximately $0.04 per share for the full year. The company is reliant on its cardiac rhythm management (CRM) and drug-eluting stent (DES) portfolios, which operate in mature markets subject to persistent pricing pressures, potentially stifling future revenue growth. Additionally, the firm's ability to meet internal and consensus revenue expectations may be compromised if it struggles with the integration of new acquisitions and experiences delays in launching new products.

Boston Scientific (BSX) has been analyzed by 19 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 53% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 19 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $124.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $124.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.